Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study

Autor: Wierda, W. G., Allan, J. N., Siddiqi, T., Kipps, T. J., Opat, S., Tedeschi, Alessandra, Badoux, X. C., Kuss, B. J., Jackson, S., Moreno, Carol, Jacobs, R. M. D., Pagel, J. M., Flinn, I., Pak, Y., Zhou, Cathy, Szafer-Glusman, E., Ninomoto, J., Dean, James P, James, D. F., Ghia, Paolo, Tam, C. S., Universitat Autònoma de Barcelona

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 39, iss 34
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
JOURNAL OF CLINICAL ONCOLOGY
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname

PURPOSE CAPTIVATE ( NCT02910583 ), a randomized phase II study, evaluates minimal residual disease (MRD)-guided treatment discontinuation following completion of first-line ibrutinib plus venetoclax treatment in patients with chronic lymphocytic leuk

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c35a6a06435710a766e71312c7d53b84
https://doi.org/10.1200/jco.21.00807

P669: FIXED‐DURATION (FD) IBRUTINIB + VENETOCLAX FOR FIRST‐LINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL): 3‐YEAR FOLLOW‐UP FROM THE PHASE 2 CAPTIVATE STUDY FD COHORT.

Autor: Moreno, C., Wierda, W. G., Barr, P. M., Siddiqi, T., Allan, J. N., Kipps, T. J., Trentin, L., Jacobs, R., Jackson, S., Tedeschi, A., Opat, S., Bannerji, R., Kuss, B. J., Croner, L. J., Szafer‐Glusman, E., Zhou, C., Szoke, A., Dean, J. P., Ghia, P., Tam, C. S.

Publikováno v: HemaSphere; 2022 Supplement 3, Vol. 6, p567-568, 2p

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

The biological significance of the multidrug resistance gene MRP in inversion 16 leukemias

Autor: Kuss, B. J., Deeley, R. G., Susan Cole, Willman, C. L., Kopecky, K. J., Wolman, S. R., Eyre, H. J., Callen, D. F.

Publikováno v: Scopus-Elsevier

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::7bfaa159dc50539d118b628df6cac989
http://www.scopus.com/inward/record.url?eid=2-s2.0-0029865364&partnerID=MN8TOARS

Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Results from the MRD Cohort of the Phase 2 CAPTIVATE Study

Autor: Bryone J. Kuss, Ian W. Flinn, Paolo Ghia, Juthamas Sukbuntherng, Ahmed Salem, John N. Allan, Paul M. Barr, Ryan Jacobs, Cathy Zhou, Alessandra Tedeschi, Xavier Badoux, Constantine S. Tam, Karl Eckert, Danelle F. James, Tanya Siddiqi, William G. Wierda, Stephen Opat, Thomas J. Kipps, Joi Ninomoto, Kristin Russell

Background : Ibr is the only once-daily inhibitor of Bruton tyrosine kinase with significant overall survival benefit demonstrated in 2 randomized phase 3 studies in first-line CLL (RESONATE-2; ECOG1912). Both Ibr and Ven, an oral inhibitor of BCL2,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a44e9f5ae70f78fa9be8e5498cd2cacf